These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38295902)

  • 1. Prevalence and molecular characteristics of ceftazidime-avibactam resistance among carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
    Chen Y; Xiang G; Liu P; Zhou X; Guo P; Wu Z; Yang J; Chen P; Huang J; Liao K
    J Glob Antimicrob Resist; 2024 Mar; 36():276-283. PubMed ID: 38295902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of a KPC-90 Variant that Confers Resistance to Ceftazidime-Avibactam in an ST463 Carbapenem-Resistant Pseudomonas aeruginosa Strain.
    Tu Y; Wang D; Zhu Y; Li J; Jiang Y; Wu W; Li X; Zhou H
    Microbiol Spectr; 2022 Feb; 10(1):e0186921. PubMed ID: 35019766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.
    Zhang Y; Zhao J; Han J; Fan Y; Xiong Z; Zou X; Li B; Liu X; Li Z; Lu B; Cao B
    Microbiol Spectr; 2022 Apr; 10(2):e0274021. PubMed ID: 35315696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing
    Soto KD; Alcalde-Rico M; Ugalde JA; Olivares-Pacheco J; Quiroz V; Brito B; Rivas LM; Munita JM; García PC; Wozniak A
    Front Cell Infect Microbiol; 2024; 14():1410834. PubMed ID: 38903939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the
    Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F;
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of bla
    Li X; Zhang X; Cai H; Zhu Y; Ji J; Qu T; Tu Y; Zhou H; Yu Y
    Drug Resist Updat; 2023 Jul; 69():100973. PubMed ID: 37148599
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Yu W; Xiong L; Luo Q; Chen Y; Ji J; Ying C; Liu Z; Xiao Y
    Front Cell Infect Microbiol; 2021; 11():780365. PubMed ID: 34900759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of
    Li X; Zhou L; Lei T; Zhang X; Yao J; He J; Liu H; Cai H; Ji J; Zhu Y; Tu Y; Yu Y; Zhou H
    Emerg Microbes Infect; 2024 Dec; 13(1):2324068. PubMed ID: 38406830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
    Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
    Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 12. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
    Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Etest and broth microdilution for evaluating the susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to ceftaroline and of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa to ceftazidime/avibactam.
    Huang YT; Kuo YW; Teng LJ; Liao CH; Hsueh PR
    J Glob Antimicrob Resist; 2021 Sep; 26():301-307. PubMed ID: 34303027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against
    Hu Y; Chen J; Huang L; Liu C; Zhou H; Zhang R
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36753319
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant
    Contreras-Gómez MJ; Martinez JRW; Rivas L; Riquelme-Neira R; Ugalde JA; Wozniak A; García P; Munita JM; Olivares-Pacheco J; Alcalde-Rico M
    Front Pharmacol; 2022; 13():1007162. PubMed ID: 36263116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of
    Sophonsri A; Kalu M; Wong-Beringer A
    Antibiotics (Basel); 2024 May; 13(5):. PubMed ID: 38786144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic Emergence of Mismatch Repair Deficiency Facilitates Rapid Evolution of Ceftazidime-Avibactam Resistance in Pseudomonas aeruginosa Acute Infection.
    Khil PP; Dulanto Chiang A; Ho J; Youn JH; Lemon JK; Gea-Banacloche J; Frank KM; Parta M; Bonomo RA; Dekker JP
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
    Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
    Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms Driving the
    Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
    mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014-2021.
    Wang JL; Lai CC; Tsai YW; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2024 Apr; 63(4):107105. PubMed ID: 38325719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.